Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases

Title:Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases

Volume: 16 Issue: 2

Author(s): Dinara F. Mesitskaya, Abram L. Syrkin, Marina G. Aksenova, Yong Zhang, Andrey A. Zamyatnin Jr.*Philipp Y. Kopylov*

Affiliation:

• Sechenov First Moscow State Medical University, Moscow,Russian Federation

• Sechenov First Moscow State Medical University, Moscow,Russian Federation

Keywords: Inhibitors of thromboxane A2-synthase, pharmacogenetics, thromboxane A synthase, thromboxane, cardiovascular diseases, prostaglandins.

Abstract: Atherothrombosis-related diseases are one of the world’s leading causes of mortality, and thus the search for new therapeutic approaches in this area remains a very urgent task. Modern pharmacogenomic technologies make it possible to obtain valuable data on disease pathogenesis and optimal therapeutic approaches. One promising research direction is the study of the thromboxane A2 - thromboxane A synthase - thromboxane A2 receptor axis. This review summarizes the recent evidence and suggests that systematic works in this area are creating new and promising opportunities in the treatment of patients with cardiovascular diseases.

Cite this article as:

Mesitskaya F. Dinara , Syrkin L. Abram , Aksenova G. Marina , Zhang Yong , Zamyatnin Jr. A. Andrey *, Kopylov Y. Philipp *, Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2018; 16 (2) . https://dx.doi.org/10.2174/1871525716666180724115132